| Mrs Jennifer Kathleen Thompson, MSN, APRN, AGACNP-BC | |
|
2728 Sunset Blvd, Suite 300, West Columbia, SC 29169-4840 | |
| (803) 744-4940 | |
| (803) 744-4938 |
| Full Name | Mrs Jennifer Kathleen Thompson |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 8 Years |
| Location | 2728 Sunset Blvd, West Columbia, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265979827 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LA2200X | Nurse Practitioner - Adult Health | 20694 (South Carolina) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Elite Patient Care Of South Carolina Pc | 1951672617 | 118 |
News Archive
LifeVantage Corporation, the maker of Protandim®, a clinically proven, science-based therapy for oxidative stress, announced today that a new peer-reviewed study involving Protandim® was published in the scientific journal PLoS ONE. The study, conducted by researchers at Louisiana State University, examined the biochemical mechanisms that underlie the ability of Protandim® to suppress tumors in mice. That ability was previously demonstrated by the authors in a study involving a mouse two-stage model of chemically-induced skin cancer.
The latest episode in the American Chemical Society's (ACS') award-winning Global Challenges/Chemistry Solutions podcast series describes a potential new approach for treating urinary tract infections (UTIs) - which affect millions of people annually - without traditional antibiotics. Because it involves non-antibiotic compounds, the approach would not contribute to the growing problem of antibiotic-resistant bacteria, or "superbugs."
Meeting a young patient with Zellweger syndrome, a rare, life-threatening genetic disease, started a scientific investigation that culminated with an unexpected discovery.
HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted HeartWare conditional approval to begin enrollment in an Investigational Device Exemption (IDE) destination therapy clinical study for the HeartWare® Ventricular Assist System.
When treating prostate cancer with radiation therapy, side effects such as urinary problems and rectal pain and bleeding are a concern, as is impact on the patient's overall quality of life. So when new, more efficient treatment methods are developed, one important question is whether better treatment comes at the cost of increased side effects and decreased quality of life.
› Verified 5 days ago
| Entity Name | Ch Specialty Services Sc Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275915522 PECOS PAC ID: 6608182993 Enrollment ID: O20150901002450 |
News Archive
LifeVantage Corporation, the maker of Protandim®, a clinically proven, science-based therapy for oxidative stress, announced today that a new peer-reviewed study involving Protandim® was published in the scientific journal PLoS ONE. The study, conducted by researchers at Louisiana State University, examined the biochemical mechanisms that underlie the ability of Protandim® to suppress tumors in mice. That ability was previously demonstrated by the authors in a study involving a mouse two-stage model of chemically-induced skin cancer.
The latest episode in the American Chemical Society's (ACS') award-winning Global Challenges/Chemistry Solutions podcast series describes a potential new approach for treating urinary tract infections (UTIs) - which affect millions of people annually - without traditional antibiotics. Because it involves non-antibiotic compounds, the approach would not contribute to the growing problem of antibiotic-resistant bacteria, or "superbugs."
Meeting a young patient with Zellweger syndrome, a rare, life-threatening genetic disease, started a scientific investigation that culminated with an unexpected discovery.
HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted HeartWare conditional approval to begin enrollment in an Investigational Device Exemption (IDE) destination therapy clinical study for the HeartWare® Ventricular Assist System.
When treating prostate cancer with radiation therapy, side effects such as urinary problems and rectal pain and bleeding are a concern, as is impact on the patient's overall quality of life. So when new, more efficient treatment methods are developed, one important question is whether better treatment comes at the cost of increased side effects and decreased quality of life.
› Verified 5 days ago
| Entity Name | Elite Patient Care Of South Carolina Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316477896 PECOS PAC ID: 1951672617 Enrollment ID: O20170731000866 |
News Archive
LifeVantage Corporation, the maker of Protandim®, a clinically proven, science-based therapy for oxidative stress, announced today that a new peer-reviewed study involving Protandim® was published in the scientific journal PLoS ONE. The study, conducted by researchers at Louisiana State University, examined the biochemical mechanisms that underlie the ability of Protandim® to suppress tumors in mice. That ability was previously demonstrated by the authors in a study involving a mouse two-stage model of chemically-induced skin cancer.
The latest episode in the American Chemical Society's (ACS') award-winning Global Challenges/Chemistry Solutions podcast series describes a potential new approach for treating urinary tract infections (UTIs) - which affect millions of people annually - without traditional antibiotics. Because it involves non-antibiotic compounds, the approach would not contribute to the growing problem of antibiotic-resistant bacteria, or "superbugs."
Meeting a young patient with Zellweger syndrome, a rare, life-threatening genetic disease, started a scientific investigation that culminated with an unexpected discovery.
HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted HeartWare conditional approval to begin enrollment in an Investigational Device Exemption (IDE) destination therapy clinical study for the HeartWare® Ventricular Assist System.
When treating prostate cancer with radiation therapy, side effects such as urinary problems and rectal pain and bleeding are a concern, as is impact on the patient's overall quality of life. So when new, more efficient treatment methods are developed, one important question is whether better treatment comes at the cost of increased side effects and decreased quality of life.
› Verified 5 days ago
| Entity Name | Lexington Health Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710634753 PECOS PAC ID: 2567872070 Enrollment ID: O20201208000922 |
News Archive
LifeVantage Corporation, the maker of Protandim®, a clinically proven, science-based therapy for oxidative stress, announced today that a new peer-reviewed study involving Protandim® was published in the scientific journal PLoS ONE. The study, conducted by researchers at Louisiana State University, examined the biochemical mechanisms that underlie the ability of Protandim® to suppress tumors in mice. That ability was previously demonstrated by the authors in a study involving a mouse two-stage model of chemically-induced skin cancer.
The latest episode in the American Chemical Society's (ACS') award-winning Global Challenges/Chemistry Solutions podcast series describes a potential new approach for treating urinary tract infections (UTIs) - which affect millions of people annually - without traditional antibiotics. Because it involves non-antibiotic compounds, the approach would not contribute to the growing problem of antibiotic-resistant bacteria, or "superbugs."
Meeting a young patient with Zellweger syndrome, a rare, life-threatening genetic disease, started a scientific investigation that culminated with an unexpected discovery.
HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted HeartWare conditional approval to begin enrollment in an Investigational Device Exemption (IDE) destination therapy clinical study for the HeartWare® Ventricular Assist System.
When treating prostate cancer with radiation therapy, side effects such as urinary problems and rectal pain and bleeding are a concern, as is impact on the patient's overall quality of life. So when new, more efficient treatment methods are developed, one important question is whether better treatment comes at the cost of increased side effects and decreased quality of life.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Jennifer Kathleen Thompson, MSN, APRN, AGACNP-BC Po Box 6069, West Columbia, SC 29171-6069 Ph: () - | Mrs Jennifer Kathleen Thompson, MSN, APRN, AGACNP-BC 2728 Sunset Blvd, Suite 300, West Columbia, SC 29169-4840 Ph: (803) 744-4940 |
News Archive
LifeVantage Corporation, the maker of Protandim®, a clinically proven, science-based therapy for oxidative stress, announced today that a new peer-reviewed study involving Protandim® was published in the scientific journal PLoS ONE. The study, conducted by researchers at Louisiana State University, examined the biochemical mechanisms that underlie the ability of Protandim® to suppress tumors in mice. That ability was previously demonstrated by the authors in a study involving a mouse two-stage model of chemically-induced skin cancer.
The latest episode in the American Chemical Society's (ACS') award-winning Global Challenges/Chemistry Solutions podcast series describes a potential new approach for treating urinary tract infections (UTIs) - which affect millions of people annually - without traditional antibiotics. Because it involves non-antibiotic compounds, the approach would not contribute to the growing problem of antibiotic-resistant bacteria, or "superbugs."
Meeting a young patient with Zellweger syndrome, a rare, life-threatening genetic disease, started a scientific investigation that culminated with an unexpected discovery.
HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted HeartWare conditional approval to begin enrollment in an Investigational Device Exemption (IDE) destination therapy clinical study for the HeartWare® Ventricular Assist System.
When treating prostate cancer with radiation therapy, side effects such as urinary problems and rectal pain and bleeding are a concern, as is impact on the patient's overall quality of life. So when new, more efficient treatment methods are developed, one important question is whether better treatment comes at the cost of increased side effects and decreased quality of life.
› Verified 5 days ago
June Taylor Clark, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: Sc House Calls Inc, 1053 Center Street, West Columbia, SC 29169 Phone: 800-491-0909 | |
Sommer Lane Kitchin, APRN Nurse Practitioner Medicare: May Accept Medicare Assignments Practice Location: 1053 Center St, West Columbia, SC 29169 Phone: 800-491-0909 | |
Tisheila Diane Whitted, APRN, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2720 Sunset Blvd, West Columbia, SC 29169 Phone: 803-791-2480 Fax: 803-936-4102 | |
Teresa Biediger Bowers, RN NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2728 Sunset Blvd, Suite 402, West Columbia, SC 29169 Phone: 803-794-7511 Fax: 803-794-7751 | |
Heather Shaw, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2858 Sunset Blvd, West Columbia, SC 29169 Phone: 803-699-9073 Fax: 866-527-0937 | |
Amy S Shenkar, ACNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2720 Sunset Blvd, West Columbia, SC 29169 Phone: 803-791-2480 Fax: 803-936-4102 | |
Dr. Elizabeth M Mcmicken, DNP, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 131 Sunset Ct, West Columbia, SC 29169 Phone: 803-796-2222 Fax: 803-796-7839 |